References

Salvage surgery in recurrent oral squamous cell carcinoma

2021 · External reference

Histologic characteristics and tumor spread of recurrent glottic carcinoma: analysis on whole-organ sections and comparison with tumor spread of primary glottic carcinomas

10.1002/hed.20502 · 2007 · External reference

Natural course of distant metastases following radiotherapy or chemoradiotherapy in HPV-related oropharyngeal cancer

10.1016/j.oraloncology.2012.07.015 · 2013 · External reference

The role of salvage surgery in patients with recurrent squamous cell carcinoma of the oropharynx

10.1002/cncr.24595 · 2009 · External reference

Outcomes of salvage surgery with free flap reconstruction for recurrent oral and oropharyngeal cancer

10.1002/lary.20743 · 2010 · External reference

Salvage surgery for recurrent squamous cell carcinoma of the head and neck: Systematic review and meta-analysis

10.1002/hed.26898 · 2022 · External reference

Fluorescent guided sentinel lymph mapping of the oral cavity with fluorescent-labeled tilmanocept

10.1002/lary.31014 · 2024 · External reference

Estimating survival after salvage surgery for recurrent oral cavity cancer

10.1001/jamaoto.2017.0001 · 2017 · External reference

Nivolumab for recurrent squamous-cell carcinoma of the head and neck

10.1056/nejmoa1602252 · 2016 · External reference

Salvage surgery for squamous cell carcinoma of the head and neck in the era of immunotherapy: Is it time to clarify our guidelines?

10.1002/cncr.31717 · 2018 · External reference

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

10.1016/s1470-2045(16)30066-3 · 2016 · External reference

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

10.1016/s0140-6736(19)32591-7 · 2019 · External reference

Oncologic outcomes of salvage surgery and immune checkpoint inhibitor therapy in recurrent head and neck squamous cell carcinoma: A single-institution retrospective study

10.1002/hed.27162 · 2022 · External reference

Evolving treatment paradigms in recurrent and metastatic head and neck squamous cell carcinoma: The emergence of immunotherapy

10.21037/tcr-23-1 · 2023 · External reference

10.1016/j.radonc.2014.06.003

10.1016/j.radonc.2014.06.003 · External reference

Unresolved reference

External reference

Re-irradiation versus systemic therapy for the management of local-regionally recurrent head and neck cancer

10.1016/j.radonc.2024.110278 · 2024 · External reference

Optimising (re-)irradiation for locally recurrent head and neck cancer: Impact of dose-escalation, salvage surgery, PEG tube and biomarkers on oncological outcomes—a single centre analysis

10.1186/s13014-024-02570-y · 2025 · External reference

Reirradiation of head and neck cancers with proton therapy: Outcomes and analyses

10.1016/j.ijrobp.2016.03.053 · 2016 · External reference

Evaluation of proton therapy reirradiation for patients with recurrent head and neck squamous cell Carcinoma

10.1001/jamanetworkopen.2022.50607 · 2023 · External reference

Clinical outcome of salvage surgery in patients with recurrent oral cavity cancer: A systematic review and meta-analysis

10.1002/hed.27928 · 2024 · External reference

10.1016/s1470-2045(21)00136-4

10.1016/s1470-2045(21)00136-4 · External reference

Phase II multi-institutional clinical trial result of concurrent cetuximab and nivolumab in recurrent and/or metastatic head and neck squamous cell Carcinoma

10.1158/1078-0432.ccr-21-3849 · 2022 · External reference

Petosemtamab (MCLA-158) with pembrolizumab as first-line (1L) treatment of PD-L1+ recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): Phase 2 trial

2025 · External reference

Ficerafusp Alfa (BCA101) with pembrolizumab for recurrent or metastatic head and neck squamous cell Carcinoma: Two-year results of an expansion cohort of a phase I/Ib Trial

10.1200/jco-25-02027 · 2026 · External reference

10.1200/jco-26-01042

10.1200/jco-26-01042 · External reference